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doi:10.1016/j.gmbhs.2012.04.006Abstract Cancer has continuously occupied the top leading cause of death in Taiwan for 29
years. Thus, scientists around the world actively devote themselves to the study of cancer
therapeutics. Doxorubicin is one of the most efficient drugs in cancer therapy, but it also
produces reactive oxygen species that induce serious cytotoxicity against heart cells. Quer-
cetin, a plant-derived flavonoid, has been proven to contain potent antioxidant, antihista-
mine, antimicrobial, and anti-inflammatory properties. The aim of this study is to perform
an in vitro investigation into whether quercetin is capable of decreasing doxorubicin-
induced cytotoxicity and promoting the cell repair system in cardiomyocyte H9C2 cells. Pro-
teomic analysis was performed to investigate the quercetin-induced responses.
Copyright ª 2012, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Doxorubicin is a chemotherapy drug commonly used in
many types of cancer treatment. The main mechanism of
doxorubicin is chelating DNA, inhibiting topoisomerase II,of Applied Science, National
er 521, Nanda Road, Hsinchu
e.edu.tw (H.-C. Chou).
an Genomic Medicine and Biomaand then producing free radicals to kill cancer cells.1
Because myocardial is particularly sensitive to reactive
oxygen species (ROS), cumulative doxorubicin in vivo will
cause irreversible damage to heart cells and restrict the
clinical use of this drug.2 To reduce the risk of developing
cardiac cell damage by doxorubicin, we can “domesticate”
the myocardial cells before drug treatment. Therefore, it
can protect the myocardial cells from the damage caused
by doxorubicin.
The aims that we will explore are the effect of quercetin
to protect H9C2 cells from doxorubicin-induced cytotoxicityrker Society. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Effect of quercetin on the viability of doxorubicin-
treated H9C2 cells. The cell viabilities were determined using
MTT cell viability assay.
52 J.-Y. Chen et al.and the regulating signals and protective mechanisms of
quercetin in response to doxorubicin exposure.3 Herein, we
used two-dimensional gel electrophoresis (2D-DIGE) and
identified the differentially expressed proteins between
untreated control cells and doxorubicin-treated cells.
Materials and methods
Cell lines, cell culture, and cell treatment
The rat cardiomyocyte cell line H9C2 was maintained in
Dulbecco modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) fetal calf serum (FCS), l-glutamine (2 mM),
streptomycin (100 mg/ml), and penicillin (100 IU/ml). All
cells were incubated in a humidified incubator at 37C with
5% CO2. There are three groups in this study: untreated
control cells, cells treated with 0.5 mM doxorubicin for 24
hours, and cells pretreated with 200 mM Quercetin for 4
hours and then incubated with 0.5 mM doxorubicin for 24
hours.
MTT cell viability assay
After specific treatment, 50 ml of MTT working solution was
added to the cells in each well followed by incubation at
37C for 4 hours. The supernatant was carefully removed. A
total of 100 ml of dimethyl sulfoxide (DMSO) was added to
each well and the plates were shaken for 20 minutes. The
absorbance of the samples was then measured at a wave-
length of 540 nm in a multiwell-plate reader. Values were
normalized against the untreated samples and were aver-
aged from four independent measurements.
Immunoblotting
Cells were washed in cold buffer solution PBS (phosphate
buffered saline) and scraped in lysis buffer. Protein samples
were diluted in Laemmli sample buffer and separated by
one-dimensional (1D) sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDSePAGE) according to
standard procedures. Gel-separated proteins were elec-
troblotted onto polyvinylidene difluoride membranes.
Membranes were blocked for 30 minutes with 5% (w/v)
bovine serum albumin in Tris-buffered saline with 0.1%
Tween 20 (TBS-T). Membranes were incubated overnight
with primary antibody solution in TBS-T. Membranes were
washed in TBS-T and then probed with peroxidase-coupled
secondary antibody. After extensive washes in TBS-T,
immuno-reactive proteins were visualized using the
enhanced chemiluminescence method (BioVision, CA, USA).
2D-DIGE and gel image analysis
Protein sample lysed in 2D lysis buffer was labeled with
either Cy3 or Cy5 for comparison on the same 2D gel. A pool
of all samples was also prepared and labeled with Cy2 at
the same molar ratio of Cy2/mg protein as an internal
standard to be run on all gels to facilitate image matching
and cross-gel statistical comparison. Labeling reactions
were performed in the dark on ice for 30 minutes and thenquenched with a 20-fold molar excess of free L-lysine to
dye for 10 minutes. The differentially Cy3- and Cy5- labeled
samples were mixed with the Cy2-labeled internal standard
and reduced with DTT for 10 minutes. Carrier ampholyte
IPG (immobilized pH gradient) buffer, pH 3e10, was added
and the final volume was adjusted to 450 ml with 2D lysis
buffer. Immobilized nonlinear pH gradient strips (pH 3e10,
24 cm) were rehydrated with the Cy-labeled samples in the
dark at room temperature overnight. Isoelectric focusing
was then performed using a Multiphor II apparatus (GE
Healthcare, Uppsala, Sweden) for a total of 62.5 kVh at
20C. Strips were equilibrated in 6 M urea, 30% (v/v) glyc-
erol, 1% SDS (w/v), 100 mM TriseHCl (pH 8.8) with 65 mM
DTT for 15 minutes, and then in the same buffer containing
240 mM iodoacetamide for 15 minutes. The equilibrated IPG
strips were transferred onto 24 20-cm 12.5% poly-
acrylamide gels cast between low-fluorescence glass
plates. The strips were overlaid with 0.5% (w/v) low-
melting-point agarose in running buffer containing bromo-
phenol blue. The gels were run in an Ettan (GE Healthcare,
Uppsala, Sweden) 12 gel tank at 4W per gel at 10C. 2D-
DIGE gels were scanned directly between the low-
fluorescence glass plates using an Ettan DIGE imager.
Image analysis was performed using DeCyder 2-D Differen-
tial Analysis software version 7.0 (GE Healthcare, Uppsala,
Sweden) to co-detect, normalize, and quantify the protein
features in the images. Features detected from nonprotein
sources were filtered out. Protein spots displaying 1.5-fold
average increase or decrease in abundance with a p value <
0.05 were selected for protein identification.
Protein identification by matrix-assisted laser
desorption/ ionization time of flight mass
spectrometer (MALDI-TOF MS)
For MALDI-TOF MS, 0.5 ml of tryptic digest was mixed with
0.5 ml of matrix solution and spotted onto an anchor chip
target plate and air-dried. The peptide mass fingerprints
were acquired on an Autoflex III mass spectrometer (Bruker
Daltonics Inc., Bremen, Germany) in the reflector mode.
Peaks were used to generate a peptide mass fingerprint,
which was searched against the updated SwissProt/TrEMBL
database using Mascot software version 2.2.06 (Matrix
Figure 2 Functional classification of quercetin-induced
changes in the protein expression of H9C2 cells.
Quercetin displays cardioprotective effects 53Science, London, UK) and the following parameters: rattus,
tryptic digest with a maximum of 1 missed cleavage, car-
bamidomethylation of cysteine, partial protein N-terminal
acetylation, partial methionine oxidation and partial
modification of glutamine to pyroglutamate, and a mass
tolerance of 100 ppm.
Immunostaining and fluorescence microscopy
For immunofluorescence staining, H9C2 cells plated on
coverslips and the attached cells washed twice with PBS.
Localization of selected proteins was assessed using
primary antibody and incubated with cells at room
temperature for 1 hour. After three PBS washes, samples
were incubated with appropriate fluorescently labeled
secondary antibodies. For localization of filamentous actin,
cells were incubated with 0.1 mg/ml Alexa 568ephalloidin
(SigmaeAldrich, OR, USA) for 45 minutes at 37C. Coverslips
were then washed three times with PBS and at least twice
with ddH2O before being mounted in Vectashield (Vector
Laboratories, CA, USA) mounting medium. Coverslip edges
were sealed with nail polish onto glass slides and dried in
the dark at 4C. For image analysis, cells were imaged using
a fluorescence microscope.Results
Our data demonstrated that quercetin was able to rescue
the viability of doxorubicin-treated H9C2 cells (Fig. 1).
However, quercetin can increase the toxic effect of doxo-
rubicin on liver cancer HepG2 cells (data not shown). 2D-
DIGE and MALDI-TOF analysis showed that quercetin regu-
lated the expression of proteins related to cell migration,
biosynthetic pathway, metabolic pathway, signal trans-
duction, gene regulation, and protein folding (Fig. 2). To
the best of our knowledge, this study is the first to
demonstrate the ability of quercetin to protect car-
diomyocytes from the cytotoxicity of doxorubicin and also
further provide the cellular mechanism to elucidate quer-
cetin-induced cardiomyocytes response via proteomic
analysis.Discussion
Our preliminary data show that quercetin reduces but
enhances the cytotoxicity of doxorubicin on car-
diomyocytes H9C2 cells and liver cancer HepG2 cells,
respectively. This observation suggests that a combination
of quercetin and doxorubicin on liver cancer treatment
might be a helpful option for the clinical liver cancer trial.References
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